Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
| Autor: | Neil Fleshner, Sally Hanna, Thierry Roumeguere, Alexandre R. Zlotta, Claude Schulman, Sandrine Rorive, Sultan Alkhateeb, Mischel G. Neill, Michael A.S. Jewett, Sas Barmoshe, Shahrokh F. Shariat, D. Kakiashvili, Peter J. Boström, Bas W.G. van Rhijn, Michel Petein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Oncology
p53 medicine.medical_specialty Urology high risk lcsh:RC870-923 cyclinD1 metallothionein 9 Risk groups Refractory Internal medicine medicine long-term response BCG Bcl-2 Survival analysis Univariate analysis Bladder cancer p21 business.industry waf1/cip medicine.disease lcsh:Diseases of the genitourinary system. Urology Surgery Log-rank test EORTC Immunohistochemistry bladder cancer Original Article Non muscle invasive business |
| Zdroj: | Urology Annals, Vol 3, Iss 3, Pp 119-126 (2011) Urology Annals |
| ISSN: | 0974-7834 0974-7796 |
| Popis: | Background and Objectives: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. Materials and Methods: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. Results: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|